Loading
ARS Pharmaceuticals, Inc. Stock: price and insider trades · United States
US·Mcap US$399.8M
No insider purchase over the last 90 days. The latest was filed 27 Mar 2024.
ARS Pharmaceuticals, Inc.: what insiders have been doing
ARS Pharmaceuticals, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 22 filings came from 9 insiders.
There is no open-market purchase to report; the filings show 2 sales by 2 insiders. The totals exclude 2 filings filed without an amount.
Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (5,458 companies, median 22 filings), a count of 22 filings is typical. Our records for ARS Pharmaceuticals, Inc. go back to 2021, with 8 purchases and 40 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 84.3 m USD and net income at -171.3 m USD.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
160
Thresholds
n/a
Buy Volume
€35M
8 ops. · all time
Sell Volume
€31M
40 ops. · all time
Who traded when
BuySaleRichard E. Lowenthal4 sales
Flynn James E3 sales
Shawver Laura3 sales
Sarina Tanimoto2 sales
Alexander A. Fitzpatrick1 sale
Eric Karas1 sale
+1 other insider
Since the insiders bought
- +22.2%Entry US$10.22 · Close at T+365 US$12.49
- +268.6%Entry US$3.92 · Close at T+365 US$14.45
- +67.9%Entry US$7.11 · Close at T+365 US$11.94
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate ARS Pharmaceuticals, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$22.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,036 of 24,148 companies
25.0
score / 100
Value5
Quality45
FCF yld-43%
Earn yld-43%
EV/EBITDA·
ROE-210%
Gross mgn76%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.02
Analyst consensus
4 analystsStrong buy
US$15.00Target US$22.50(+460%)US$30.00
Income statement
RevenueUS$84.3M
Gross profitUS$63.9M76% margin
EBITDA-US$168.8M-200% margin
Net income-US$171.3M-184.2% margin
Valuation
PER (forward)-4.5x
P/Book31.9x
Beta1.08
Balance sheet & cash
Market capUS$399.8M
Total debtUS$96.4M
Free Cash Flow-US$171.2M
Debt / Equity1372%
Profitability & ownership
ROE-210.3%
ROA-48.0%
% insiders16.2%
% institutions92.1%
Last declaration on 1 October 2026
Declarations160 total
100,000 shares@ US$4.2610.097% mcap36.4% of flowCommonSEC144:0001950047-26-009969
100,000 shares@ US$4.31560.099% mcap58.0% of flowCommonSEC144:0001950047-26-009892
14,064 shares@ US$4.96030.016% mcap21.8% of flowCommonSEC144:0001950047-26-009329
35,000 shares@ US$5.0570.042% mcap11.8% of flowCommonSEC144:0001950047-26-009340
75,000 shares@ US$5.61410.099% mcap28.0% of flowCommonSEC144:0001950047-26-009120
19,805 shares@ US$5.83510.027% mcap7.7% of flowCommonSEC144:0001950047-26-009066
45,388 shares@ US$6.01150.064% mcap21.6% of flowCommonSEC144:0001950047-26-008961
63,289 shares@ US$5.81620.087% mcap29.2% of flowCommonSEC144:0001950047-26-008852
25,000 shares@ US$5.91880.035% mcap11.7% of flowCommonSEC144:0001950047-26-008488
25,000 shares@ US$5.92640.035% mcap9.8% of flowCommonSEC144:0001950047-26-008459
50,000 shares@ US$6.44690.076% mcap21.5% of flowCommonSEC144:0001950047-26-008376
25,000 shares@ US$6.44680.038% mcap12.8% of flowCommonSEC144:0001950047-26-008389
50,000 shares@ US$6.31770.075% mcap21.1% of flowCommonSEC144:0001950047-26-008357
49,401 shares@ US$6.29930.074% mcap24.7% of flowCommonSEC144:0001950047-26-008362
25,000 shares@ US$10.000.031% mcap78.2% of flowCommonSEC144:0001950047-26-006004
3,355 shares@ US$10.000.0042% mcap100.0% of flowCommonSEC144:0001950047-26-005998
3,355 sharesCommon StockSEC:0001398595-26-000004:0
25,000 sharesCommon StockSEC:0001951287-26-000004:0
25,000 sharesCommon StockSEC:0001951287-26-000004:1
250,000 shares0Common StockSEC:0001580787-25-000004:0
30,000 shares@ US$0.843.3% of flowCommon StockSEC:0001951238-25-000005:0
21,828 shares@ US$0.6417.9% of flowCommon StockSEC:0001380762-25-000005:0
50,000 shares@ US$14.48696.5% of flowCommon StockSEC:0001415889-25-022761:0
12,500 shares@ US$1.509.7% of flowCommon StockSEC:0001415889-25-022760:0
12,344 shares@ US$14.02541.6% of flowCommon StockSEC:0001415889-25-022638:0
25 of 160 declarations
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a company focused on developing treatments for allergies and respiratory diseases. It is listed on NASDAQ under the ticker ARS.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
